1. Home
  2. ACU vs PBYI Comparison

ACU vs PBYI Comparison

Compare ACU & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACU
  • PBYI
  • Stock Information
  • Founded
  • ACU 1867
  • PBYI 2010
  • Country
  • ACU United States
  • PBYI United States
  • Employees
  • ACU N/A
  • PBYI N/A
  • Industry
  • ACU Industrial Machinery/Components
  • PBYI Biotechnology: Pharmaceutical Preparations
  • Sector
  • ACU Consumer Discretionary
  • PBYI Health Care
  • Exchange
  • ACU Nasdaq
  • PBYI Nasdaq
  • Market Cap
  • ACU 141.5M
  • PBYI 154.1M
  • IPO Year
  • ACU N/A
  • PBYI N/A
  • Fundamental
  • Price
  • ACU $39.78
  • PBYI $2.93
  • Analyst Decision
  • ACU
  • PBYI Strong Buy
  • Analyst Count
  • ACU 0
  • PBYI 1
  • Target Price
  • ACU N/A
  • PBYI $7.00
  • AVG Volume (30 Days)
  • ACU 8.5K
  • PBYI 380.4K
  • Earning Date
  • ACU 04-21-2025
  • PBYI 05-01-2025
  • Dividend Yield
  • ACU 1.50%
  • PBYI N/A
  • EPS Growth
  • ACU N/A
  • PBYI 37.78
  • EPS
  • ACU 2.45
  • PBYI 0.62
  • Revenue
  • ACU $194,489,991.00
  • PBYI $230,468,000.00
  • Revenue This Year
  • ACU $4.87
  • PBYI N/A
  • Revenue Next Year
  • ACU $3.65
  • PBYI $3.27
  • P/E Ratio
  • ACU $16.17
  • PBYI $4.73
  • Revenue Growth
  • ACU 1.56
  • PBYI N/A
  • 52 Week Low
  • ACU $32.85
  • PBYI $2.23
  • 52 Week High
  • ACU $50.00
  • PBYI $6.06
  • Technical
  • Relative Strength Index (RSI)
  • ACU 54.34
  • PBYI 38.50
  • Support Level
  • ACU $39.00
  • PBYI $3.14
  • Resistance Level
  • ACU $40.95
  • PBYI $3.18
  • Average True Range (ATR)
  • ACU 1.21
  • PBYI 0.19
  • MACD
  • ACU -0.04
  • PBYI -0.07
  • Stochastic Oscillator
  • ACU 56.46
  • PBYI 4.23

About ACU Acme United Corporation.

Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: